In the high-stakes arena of pharmaceutical patent litigation, the line between a patentable innovation and an unpatentable medical procedure is often measured in milligrams and intervals. For decades, Canadian intellectual property law has walked a tightrope: how do we reward life sciences companies for discovering optimal ways to administer drugs, while simultaneously protecting the unfettered professional judgment of physicians treating patients? With the Supreme Court of Canada’s recent landmark decision in Pharmascience Inc. v. Janssen Inc., the highest court has provided a definitive answer, fundamentally reshaping the patentability of therapeutic methods.
As recently detailed in an analysis by Lavery, the SCC dismissed an invalidity challenge brought by generic manufacturer Pharmascience, maintaining Janssen’s dosing-regimen patent. But the implications of this ruling extend far beyond the specific schizophrenia treatment at the heart of the dispute. For Canadian IP counsel, patent agents, and pharmaceutical litigators, the decision offers a critical new roadmap for drafting, prosecuting, and defending dosing regimens.
The Anatomy of the Dispute: When is a Dose a 'Method'?
To understand the gravity of the SCC’s ruling, one must revisit the longstanding Canadian prohibition against patenting "methods of medical treatment." Historically, the courts have held that patents cannot restrict a medical professional's ability to exercise their skill and judgment. You can patent a scalpel, but you cannot patent the surgical technique used to wield it. You can patent a pill, but you cannot patent the clinical decision to adjust a patient's dosage based on their real-time physiological response.
In Pharmascience v. Janssen, the patent in question covered a specific dosing regimen for paliperidone palmitate (marketed as Invega Sustenna). The claims detailed a precise loading dose followed by specific maintenance doses administered at specific intervals. Pharmascience argued that because the administration requires a physician's involvement, the patent inherently encroached upon the forbidden territory of medical treatment methods.
The Supreme Court disagreed, cementing a crucial distinction in Canadian patent law: the difference between a fixed regimen and a variable one.
"The distinction lies not in whether a physician is involved in administering the drug, but whether the patent claims restrict the physician's ability to exercise their professional skill and judgment in applying the invention. A fixed dosage schedule is a vendible product; an instruction to adjust a dose based on clinical observation is a medical method."
The SCC's Refined Test: Skill vs. Execution
The SCC clarified that the mere fact that a physician must prescribe or administer a drug does not invalidate a patent claim. Every prescription drug requires a doctor's initial judgment to determine if the medication is appropriate for the patient. However, this initial "prescribing decision" is separate from the "execution" of the patent claims.
If the patent claims dictate a regimen that is fixed—meaning the "how" and "when" are pre-determined by the patent itself—the physician is merely executing the invention. If, conversely, the claims require the physician to monitor the patient's blood levels, assess side effects, and adjust the dosage accordingly, the patent is attempting to monopolize the physician's ongoing clinical judgment.
Mapping the Boundaries of Patentability
For patent prosecutors and litigators, the SCC's framework creates a clear dichotomy. The following table illustrates how different claim features are likely to be treated under the newly clarified standard:
| Claim Feature | Likely Status Under SCC Framework | Rationale |
|---|---|---|
| Fixed dosage amount (e.g., "150 mg") | Patentable | No ongoing physician judgment required to measure the dose. |
| Fixed time intervals (e.g., "administered on Day 1 and Day 8") | Patentable | Execution is mechanical; schedule is pre-determined by the inventors. |
| Titration instructions (e.g., "increasing the dose until symptoms abate") | Unpatentable | Relies entirely on the subjective clinical observation of the physician. |
| Conditional dosing (e.g., "administering 100mg if renal clearance is < 50 mL/min") | High Risk / Context Dependent | May be viewed as a diagnostic step intertwined with clinical judgment, though some objective metrics may survive. |
Strategic Implications for the Life Sciences Bar
The SCC's decision in Pharmascience v. Janssen is a decisive victory for innovative pharmaceutical companies, providing them with greater certainty when protecting the massive investments required to run Phase II and Phase III clinical trials focused on dosage optimization. However, it also demands a strategic pivot for both patent drafters and litigators.
1. A New Paradigm for Patent Drafters
Patent agents drafting life sciences applications for the Canadian market must now be meticulous in their language. The goal is to draft claims that describe a complete, self-contained invention that operates independently of the doctor's real-time clinical assessment.
- Eliminate "Titration" Language: Words like "adjusting," "monitoring," "titrating," or "evaluating" within the claims are red flags that invite invalidity challenges.
- Frame as "Use" Claims: Canadian practice already favors "use" claims (e.g., "Use of Compound X for treating Disease Y, wherein Compound X is formulated for administration at [fixed dose]...") over "method of treatment" claims. The SCC ruling reinforces the necessity of this structure.
- Standardize Patient Subpopulations: If a dosage is specific to a certain type of patient (e.g., pediatric vs. adult), draft separate, fixed claims for each subpopulation rather than a single claim instructing the doctor to choose based on the patient's profile.
2. Pivots in PMNOC Litigation
For generic pharmaceutical companies relying on the Patented Medicines (Notice of Compliance) Regulations (PMNOC), the "method of medical treatment" attack has historically been a reliable weapon against secondary patents. The SCC has now significantly blunted this weapon when deployed against fixed-dose regimens.
Moving forward, generic challengers will likely need to shift their focus. If they cannot invalidate a fixed-dose patent on subject-matter grounds, we can expect a surge in challenges based on obviousness and utility. Generics will increasingly argue that while a specific dosing interval might be patentable subject matter, arriving at that interval was routine optimization for a person skilled in the art, rather than an inventive step.
The Horizon: Personalized Medicine and AI-Driven Dosing
While the SCC has provided welcome clarity for traditional pharmaceuticals, a storm is brewing on the horizon. The future of medicine is increasingly personalized, driven by biologics, gene therapies, and AI-optimized treatment plans where dosages are hyper-customized to an individual's real-time biomarkers.
How will the SCC's "fixed vs. variable" framework apply when a patent claims an algorithmic method for continuously adjusting a patient's dosage based on wearable sensor data? If the adjustment is made by a machine rather than a physician's "professional skill and judgment," does it bypass the prohibition entirely? Or will courts view the algorithm merely as a proxy for medical judgment?
For now, Pharmascience v. Janssen establishes a firm baseline: precision in patent drafting is paramount. By drawing a clear line between the vendible product of a fixed regimen and the unpatentable art of clinical practice, the Supreme Court has secured the immediate future of pharmaceutical innovation in Canada. But as medicine evolves from static pills to dynamic, data-driven therapies, Canadian IP professionals must remain prepared to test these newly defined boundaries once again.